Wdzieczak-Bakala J, Guigon M, Lenfant M, Frindel E
Biomed Pharmacother. 1983;37(9-10):467-71.
This paper describes a large scale extraction procedure which allows the preparation of a stable CFU-S inhibitor from fetal calf bone marrow. The use of BioGel P-2 gels results in an increase of the specific activity of the inhibitor as well as in the yield of the preparation. When injected into mice, the inhibitory fraction (Ve/Vo 1.17-1.8) prevent CFU-S entry into cycle after cytosine arabinoside at a dose of 4 micrograms per mouse. When administered during lethal protocols of Ara-C treatment, it significantly increases the percentage of surviving animals. Thus, this low molecular weight factor (below 2,000 D), devoid of species-specificity, enhances the tolerance of animals to high doses of chemotherapy and might be of interest in cancer treatment.
本文描述了一种大规模提取方法，该方法可从胎牛骨髓中制备出稳定的集落形成单位脾（CFU-S）抑制剂。使用生物凝胶P-2凝胶可提高抑制剂的比活性以及制备产量。当将抑制级分（洗脱体积/总体积为1.17 - 1.8）注射到小鼠体内时，在每只小鼠注射4微克阿糖胞苷后，可阻止CFU-S进入细胞周期。当在阿糖胞苷致死治疗方案期间给药时，它可显著提高存活动物的百分比。因此，这种低分子量因子（低于2000道尔顿），不具有物种特异性，可增强动物对高剂量化疗的耐受性，在癌症治疗中可能具有重要意义。
